JP2021516254A5 - - Google Patents

Info

Publication number
JP2021516254A5
JP2021516254A5 JP2020560859A JP2020560859A JP2021516254A5 JP 2021516254 A5 JP2021516254 A5 JP 2021516254A5 JP 2020560859 A JP2020560859 A JP 2020560859A JP 2020560859 A JP2020560859 A JP 2020560859A JP 2021516254 A5 JP2021516254 A5 JP 2021516254A5
Authority
JP
Japan
Prior art keywords
antibody
seq
antibody according
sialyl
stn
Prior art date
Application number
JP2020560859A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019147152A5 (https=
JP2021516254A (ja
JP7324777B2 (ja
Filing date
Publication date
Priority claimed from PT110526A external-priority patent/PT110526B/pt
Application filed filed Critical
Publication of JP2021516254A publication Critical patent/JP2021516254A/ja
Publication of JPWO2019147152A5 publication Critical patent/JPWO2019147152A5/ja
Publication of JP2021516254A5 publication Critical patent/JP2021516254A5/ja
Application granted granted Critical
Publication of JP7324777B2 publication Critical patent/JP7324777B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020560859A 2018-01-26 2019-01-17 腫瘍抗原に対するl2a5抗体またはその機能的断片 Active JP7324777B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PT110526 2018-01-26
PT110526A PT110526B (pt) 2018-01-26 2018-01-26 Anticorpo, fragmento funcional ou sonda do mesmo contra antigénios tumorais
PCT/PT2019/000001 WO2019147152A1 (en) 2018-01-26 2019-01-17 L2a5 antibody or functional fragment thereof against tumour antigens

Publications (4)

Publication Number Publication Date
JP2021516254A JP2021516254A (ja) 2021-07-01
JPWO2019147152A5 JPWO2019147152A5 (https=) 2022-02-24
JP2021516254A5 true JP2021516254A5 (https=) 2022-02-24
JP7324777B2 JP7324777B2 (ja) 2023-08-10

Family

ID=65244573

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020560859A Active JP7324777B2 (ja) 2018-01-26 2019-01-17 腫瘍抗原に対するl2a5抗体またはその機能的断片

Country Status (14)

Country Link
US (1) US11353460B2 (https=)
EP (1) EP3743726B1 (https=)
JP (1) JP7324777B2 (https=)
CN (1) CN113287018B (https=)
AU (1) AU2019211035B2 (https=)
BR (1) BR112020014931A2 (https=)
CA (1) CA3089300A1 (https=)
EA (1) EA202091760A1 (https=)
IL (1) IL276208B1 (https=)
MX (1) MX2020007828A (https=)
PT (1) PT110526B (https=)
SG (1) SG11202006897VA (https=)
WO (1) WO2019147152A1 (https=)
ZA (1) ZA202005023B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4310100A4 (en) * 2021-03-18 2025-05-14 Hirosaki University MONOCLONAL ANTIBODY THAT SPECIFICALLY BINDS TO A SUGAR CHAIN IN WHICH A TERMINAL SIALIC ACID RESIDUE IS BOUND TO GALACTOSE WITH A α2,6 LINKAGE AND METHOD FOR MEASURING THE SUGAR CHAIN WITH A TERMINAL SIALIC ACID RESIDUE BOUND TO GALACTOSE WITH A α2,6 LINKAGE
US20240197882A1 (en) * 2021-04-20 2024-06-20 Ramot At Tel-Aviv University Ltd. Humanized anti-sialyl-tn glycan antibodies and uses thereof
GB2619976A (en) 2022-06-24 2023-12-27 Cellmabs S A Humanised antibodies or functional fragments thereof against tumour antigens
CN121219019A (zh) 2023-05-05 2025-12-26 百欧恩泰欧洲股份公司 用于增强靶向癌症相关抗原的采用新型连接子-有效载荷系统的抗体药物偶联物
WO2026057354A1 (en) * 2024-09-10 2026-03-19 Invox Pharma Limited Anti-sialyl-tn antigen-binding proteins

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU584417B2 (en) 1985-04-01 1989-05-25 Lonza Group Ag Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
ATE123066T1 (de) * 1988-03-11 1995-06-15 Biomembrane Inst Monoklonale antikörper und herstellung eines impfstoffes gegen menschliche krebsantigene durch immunisierung mit menschlichem und tierischem mucin und mit synthetischen gluciden- trägerkonjugaten.
CA2189356A1 (en) 1994-05-02 1995-11-09 Ting Chi Wong Process for preparation of glycosides of tumor-associated carbohydrate antigens
EP0996455B1 (en) 1997-04-16 2009-12-16 Sloan-Kettering Institute For Cancer Research Alpha-o-linked glycoconjugates with clustered (2,6)-st epitopes, methods of preparation and uses thereof
CU22731A1 (es) * 1998-02-05 2002-02-28 Centro Inmunologia Molecular Anticuerpo monoclonal que reconoce el oligosacárido ácido siálico n´glicolilado-galactosa-glucosa (ngcneu-gal-glu) en tumores malignos y composiciones farmacéuticas que los contienen
JP3809277B2 (ja) 1998-03-05 2006-08-16 生化学工業株式会社 N−アセチルグルコサミン−6−o−硫酸基転移酵素のポリペプチド及びそれをコードするdna
GB9917012D0 (en) 1999-07-20 1999-09-22 Pharmacia & Upjohn Spa Combined preparations comprising antitumor agents
EP1651955A4 (en) 2003-07-15 2007-11-21 Univ California PROCESS FOR THE DETECTION AND ANALYSIS OF N-GLYCOLYLNEURAMIC ACID (NEU5GC) IN BIOLOGICAL MATERIALS
US8148335B2 (en) 2004-06-23 2012-04-03 Children's Hospital & Research Center Oakland De-N-acetyl sialic acid antigens, antibodies thereto, and methods of use in cancer therapy
EP2083868A2 (en) 2006-10-04 2009-08-05 Københavns Universitet Generation of a cancer-specific immune response toward muc1 and cancer specific muc1 antibodies
JP5156887B2 (ja) * 2007-02-14 2013-03-06 独立行政法人科学技術振興機構 2−6シアリル6−スルホ糖鎖に対する抗体
EP2014302A1 (en) 2007-07-12 2009-01-14 Institut Curie An antibody specific for the Tn antigen for the treatment of cancer
FI20070853A0 (fi) * 2007-11-09 2007-11-09 Glykos Finland Oy Glykaania sitovat monoklonaaliset vasta-aineet
EP2287202A1 (en) 2009-08-07 2011-02-23 Dublin City University Anti-sialic acid antibody molecules
EP2524233A4 (en) 2010-01-15 2013-07-31 Univ California COMPOSITIONS AND METHOD FOR DETECTING CANCER
JP6172687B2 (ja) 2013-05-02 2017-08-02 国立研究開発法人産業技術総合研究所 シアリル化糖鎖を認識するモノクローナル抗体
WO2014191128A1 (en) 2013-05-29 2014-12-04 Cellectis Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system
KR102313341B1 (ko) 2013-08-26 2021-10-18 바이오엔테크 리서치 앤드 디벨롭먼트 인코포레이티드 시알릴-루이스 a에 대한 사람 항체 코드화 핵산
EP2990416B1 (en) 2014-08-29 2018-06-20 GEMoaB Monoclonals GmbH Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
US20180280504A1 (en) * 2014-10-10 2018-10-04 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
US11279769B2 (en) * 2015-08-31 2022-03-22 Helixmith Co., Ltd Anti-Sialyl Tn chimeric antigen receptors
EP3645703B1 (en) * 2017-05-25 2025-11-26 Instituto de Patologia e Imunologia da Universidade do Porto (IPATIMUP) Detection and isolation of cancer cells from body fluids based on a glycosylation pattern and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2021516254A5 (https=)
RU2425841C2 (ru) Получение и анализ полностью человеческих лечебных антител-производных hucal gold, специфичных к человеческому cd38
JP2020522261A5 (https=)
IL273196B2 (en) Claudin6 antibodies and methods of treating cancer
JP2020500003A5 (https=)
JP2006020633A (ja) 糸球体腎炎および他の炎症性疾患の治療のための組成物および方法
RU2014101707A (ru) АНТИ-Axl АНТИТЕЛА И ИХ ПРИМЕНЕНИЕ
JP2016516400A5 (https=)
IL265434B1 (en) Anti-cd27 antibodies
JP2018509385A5 (https=)
JP2021500916A5 (https=)
CN112513094A (zh) 结合人her2的抗体、其制备方法和用途
EP4460516A2 (en) Bispecific sars-cov-2 antibodies and methods of use
JP2017521054A5 (https=)
JP2021517459A5 (https=)
CN113227148B (zh) 抗gpc3抗体、其抗原结合片段及其医药用途
RU2020113713A (ru) Слитый белок, содержащий молекулу fgf-18
JP2018515071A5 (https=)
JP2016536988A5 (https=)
JPWO2019147152A5 (https=)
CN109021103B (zh) 抗人血管内皮生长因子的抗体及其制备方法和应用
JP2021525512A5 (https=)
JP2020521752A (ja) グロボhに対するヒト化抗体および癌治療におけるその使用
CN113651884A (zh) 人源化抗SARS-CoV-2单克隆抗体及其应用
CN115850477B (zh) 一种抗人4-1bb单克隆抗体及其应用